Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.72 |
| ▸ | MGAM | O43451 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SI | P14410 | 1/20 | 0.61 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.57 |
| ▸ | PTP4A3 | O75365 | 8/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | NAT1 | P18440 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18102852 | 1.00 | GSK3B (0.72) | GSK3BMGAMGAASIMGAM2 | |
| SCHEMBL20005777 | 0.89 | MGAM (0.68) | GSK3BMGAMGAASIMGAM2 | |
| SCHEMBL18102936 | 0.89 | MGAM (0.68) | GSK3BMGAMGAASIMGAM2 | |
| SCHEMBL10090299 | 0.89 | MGAM (0.59) | GSK3BMGAMGAASIMGAM2 | |
| SCHEMBL2065374 | 0.89 | MGAM (0.59) | GSK3BMGAMGAASIMGAM2 | |
| SCHEMBL12210310 | 0.88 | GSK3B (0.72) | GSK3BMEN1POLBBLMKMT2A | |
| SCHEMBL18102848 | 0.85 | MGAM (0.66) | GSK3BMGAMGAASIMGAM2 | |
| SCHEMBL10090298 | 0.85 | MEN1 (0.61) | GSK3BMGAMGAASIMGAM2 | |
| SCHEMBL2065559 | 0.85 | MEN1 (0.61) | GSK3BMGAMGAASIMGAM2 | |
| SCHEMBL5026018 | 0.83 | KMT2A (0.53) | GSK3BMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | GSK3B 1070/4885MGAM 4574/4885GAA 3491/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | GSK3B 1070/4885MGAM 4574/4885GAA 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.